Precision medicine franchise launch and new revenue
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Tetratherix Limited has announced the launch of a new precision medicine franchise utilizing its Tetramatrix platform, which is expected to generate immediate revenue through a partnership with Superpower Health Inc. The agreement includes an annual exclusive license payment and the purchase of Tetramatrix polymer for nasal delivery of various compounds. Tetratherix confirms that all milestones for its existing franchises are on track, with expectations for FDA approvals in the near future. The precision medicine franchise is designed to enhance Tetratherix's financial position without diverting resources from its core programs.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Earlier from Tetratherix
- Tutelix Update
- Half Yearly Report and Accounts
- TetraDerm Cohort 1 Results
- Quarterly Activities/Appendix 4C Cash Flow Report
- Executed Henry Schein Agreement
Later from Tetratherix
- Successful Completion $15M Placement
- Appendix 4E and Annual Report 2026
- Results Presentation 2026
- Application for quotation of securities - TTX
- Tetratherix Ships First US Polymer, Revenue Begins
Follow Tetratherix into a list and get an email when it puts out news.
Follow Tetratherix